Equities analysts expect Kezar Life Sciences Inc (NASDAQ:KZR) to announce earnings per share (EPS) of ($0.53) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kezar Life Sciences’ earnings. The lowest EPS estimate is ($0.58) and the highest is ($0.49). Kezar Life Sciences reported earnings per share of ($0.30) in the same quarter last year, which would indicate a negative year-over-year growth rate of 76.7%. The company is expected to announce its next earnings report on Thursday, November 14th.
According to Zacks, analysts expect that Kezar Life Sciences will report full-year earnings of ($1.98) per share for the current year, with EPS estimates ranging from ($2.10) to ($1.87). For the next fiscal year, analysts expect that the company will post earnings of ($2.38) per share, with EPS estimates ranging from ($2.75) to ($2.15). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Kezar Life Sciences.
Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.02.
A number of large investors have recently made changes to their positions in KZR. BNP Paribas Arbitrage SA raised its stake in Kezar Life Sciences by 131,900.0% during the first quarter. BNP Paribas Arbitrage SA now owns 2,640 shares of the company’s stock valued at $47,000 after buying an additional 2,638 shares during the last quarter. Rhumbline Advisers bought a new position in Kezar Life Sciences in the first quarter worth approximately $245,000. Spark Investment Management LLC grew its stake in Kezar Life Sciences by 125.3% in the first quarter. Spark Investment Management LLC now owns 21,200 shares of the company’s stock worth $376,000 after purchasing an additional 11,790 shares in the last quarter. Marshall Wace LLP bought a new position in Kezar Life Sciences in the first quarter worth approximately $704,000. Finally, MetLife Investment Advisors LLC bought a new position in Kezar Life Sciences in the first quarter worth approximately $123,000. Institutional investors and hedge funds own 52.27% of the company’s stock.
Shares of NASDAQ KZR traded down $0.13 during mid-day trading on Thursday, hitting $3.49. 52,637 shares of the stock traded hands, compared to its average volume of 107,599. The company has a debt-to-equity ratio of 0.06, a quick ratio of 20.32 and a current ratio of 20.32. Kezar Life Sciences has a 52 week low of $2.82 and a 52 week high of $36.33. The company has a market cap of $67.09 million, a price-to-earnings ratio of -1.54 and a beta of 0.85. The stock has a fifty day moving average price of $4.22 and a 200-day moving average price of $11.83.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
Read More: What is the Book Value of a Share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.